Synopsys slides 5% as post-Ansys growth worries collide with rich valuation
Synopsys shares fell about 5% as investors reacted to fresh concerns that its growth is slowing after the Ansys acquisition, alongside heightened valuation sensitivity. The drop comes after recent analyst downgrades focused on decelerating core EDA growth and the need for clearer profit-growth drivers following integration.
1) What’s driving the move
Synopsys (SNPS) is sliding after the market refocused on slowing core EDA growth and the lack of clear near-term catalysts to re-accelerate profitable growth following the Ansys combination. Recent analyst commentary has emphasized decelerating growth dynamics and elevated valuation risk, which can amplify downside on any incremental negative read-through. (ca.investing.com)
2) The backdrop investors are trading
Synopsys reported fiscal Q1 2026 results on February 25, 2026, with revenue of $2.409 billion and non-GAAP EPS of $3.77, and provided targets that include notable acquisition-related items and restructuring charges. With the stock still priced at a premium multiple, traders appear to be treating any ambiguity around the growth-to-margin path as a reason to de-risk. (news.synopsys.com)
3) Deal and integration overhang remains in focus
The Ansys deal has remained a central swing factor for the stock, with regulators previously requiring divestitures to address competition concerns, highlighting the complexity and execution burden around the combined portfolio. That integration complexity—and the need to show tangible, durable cross-sell and platform benefits—continues to shape how investors handicap forward growth. (ftc.gov)
4) What to watch next
Investors will watch for clearer evidence that Synopsys can stabilize and then re-accelerate core EDA growth while integrating Ansys, especially through product cadence and guidance commentary in upcoming quarters. Any further changes to the restructuring timeline/costs or incremental shifts in the growth outlook could keep the stock volatile given its valuation and recent downgrades. (news.synopsys.com)